Skip to main navigation Skip to search Skip to main content

Effectiveness of Mepolizumab in Patients with OCS-Dependent Severe Asthma: A Real-World Study

  • Sevim Bavbek
  • , Mona Al-Ahmad
  • , Hala Samaha
  • , Pooran Chand Kathuria
  • , Patricia Fernandez
  • , Nasser Al Busaidi
  • , Tayseer Ibrahim
  • , Bassam Mahboub
  • , Seema Haider
  • , Saeed Noibi
  • , Gur Levy
  • , Riyad Omar Al-Lehebi
  • Ankara University
  • Kuwait University
  • Ministry of Health, Kuwait
  • Ministry of Health, United Arab Emirates
  • BLK Super Specialty Hospital
  • National Thoracic Institute
  • Royal Hospital Oman
  • Hamad Medical Corporation
  • GSK
  • GSK
  • GSK
  • King Fahad Medical City
  • Alfaisal University

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Introduction: Before the availability of biologic therapies, the main treatment for patients with severe asthma in Asia, Latin America, and the Middle East was oral corticosteroids (OCS), despite long-term use causing serious adverse effects. This post hoc analysis of the NUCALA Effectiveness Study (NEST) evaluated the effectiveness of mepolizumab, an anti-interleukin-5 monoclonal antibody, in patients with severe asthma and OCS dependence from regions with limited representation in real-world studies. Methods: NEST was a multicountry, observational cohort study in adults with severe asthma from Colombia, Chile, India, Türkiye, Saudi Arabia, United Arab Emirates, Kuwait, Oman, and Qatar. Patients received ≥ 1 dose of 100 mg mepolizumab. OCS dependence was defined as receiving maintenance OCS at mepolizumab initiation or for ≥ 26 weeks during the 12 months prior. Data were collected 12 months pre- and post-initiation. Outcomes included OCS use, rate of clinically significant exacerbations (CSEs), and level of asthma symptom control. Results: Of 524 patients with OCS use data, 58.4% (n = 306) had OCS dependence pre-initiation. Mean (standard deviation) age was 49.2 (13.4) years; 73.9% (n = 226) were women. Of 251 patients with available data, 87.6% (n = 220) received lower OCS doses post-initiation and 68.9% (n = 173) stopped OCS use altogether. CSEs were reduced by 76.9% post-initiation. Of 222 patients with available data, 72.5% (n = 161) had improvements in Asthma Control Test scores post-initiation. Conclusion: In patients with severe asthma and OCS dependence from the countries studied, mepolizumab reduced OCS use and dose, asthma exacerbations, and improved symptom control.

Original languageEnglish
Pages (from-to)5481-5498
Number of pages18
JournalAdvances in Therapy
Volume42
Issue number11
DOIs
StatePublished - Nov 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Clinically significant exacerbations
  • Corticosteroid burden
  • Interleukin-5 inhibition
  • Mepolizumab
  • Oral corticosteroids
  • Severe asthma

Fingerprint

Dive into the research topics of 'Effectiveness of Mepolizumab in Patients with OCS-Dependent Severe Asthma: A Real-World Study'. Together they form a unique fingerprint.

Cite this